Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
158.14
-0.99 (-0.62%)
At close: Apr 23, 2025, 4:00 PM
158.01
-0.13 (-0.08%)
Pre-market: Apr 24, 2025, 4:09 AM EDT
Ascendis Pharma Employees
Ascendis Pharma had 1,017 employees as of December 31, 2024. The number of employees increased by 138 or 15.70% compared to the previous year.
Employees
1,017
Change (1Y)
138
Growth (1Y)
15.70%
Revenue / Employee
$370,186
Profits / Employee
-$384,889
Market Cap
9.51B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,017 | 138 | 15.70% |
Dec 31, 2023 | 879 | 82 | 10.29% |
Dec 31, 2022 | 797 | 158 | 24.73% |
Dec 31, 2021 | 639 | 157 | 32.57% |
Dec 31, 2020 | 482 | 152 | 46.06% |
Dec 31, 2019 | 330 | 114 | 52.78% |
Dec 31, 2018 | 216 | 79 | 57.66% |
Dec 31, 2017 | 137 | 36 | 35.64% |
Dec 31, 2016 | 101 | 23 | 29.49% |
Dec 31, 2015 | 78 | 23 | 41.82% |
Dec 31, 2014 | 55 | 10 | 22.22% |
Dec 31, 2013 | 45 | 7 | 18.42% |
Dec 31, 2012 | 38 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
ASND News
- 9 days ago - Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory - Seeking Alpha
- 23 days ago - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 2 months ago - Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? - Benzinga
- 2 months ago - Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs - GlobeNewsWire
- 2 months ago - Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025 - GlobeNewsWire